A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
Study of Encorafenib + Binimetinib in Patients wit hBRAFV600-Mutant Melanoma Brain Metastasis
Sponsor: Array BioPharma Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS3457
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to determine if high-dose versus standard-dose regimens of encorafenib and binimetinib are safe and have positive effects in people who have melanoma brain metastasis and also have been found by their doctor to have a mutated gene called BRAFV600. The time frame for the study is approximately 2 years.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Are you 18 years or older? Yes No
Do you have a BRAFV600 mutation? Yes No
Do you have melanoma brain metastases? Yes No
Are you able to provide a tissue and blood sample? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator